Quantitative Phosphoproteomics of CXCL12 (SDF-1) Signaling by Wojcechowskyj, Jason A. et al.
Quantitative Phosphoproteomics of CXCL12 (SDF-1)
Signaling
Jason A. Wojcechowskyj
1, Jessica Y. Lee
2, Steven H. Seeholzer
2, Robert W. Doms
1*
1Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America, 2Protein and Proteomics Core,
Children’s Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, United States of America
Abstract
CXCL12 (SDF-1) is a chemokine that binds to and signals through the seven transmembrane receptor CXCR4. The CXCL12/
CXCR4 signaling axis has been implicated in both cancer metastases and human immunodeficiency virus type 1 (HIV-1)
infection and a more complete understanding of CXCL12/CXCR4 signaling pathways may support efforts to develop
therapeutics for these diseases. Mass spectrometry-based phosphoproteomics has emerged as an important tool in
studying signaling networks in an unbiased fashion. We employed stable isotope labeling with amino acids in cell culture
(SILAC) quantitative phosphoproteomics to examine the CXCL12/CXCR4 signaling axis in the human lymphoblastic CEM cell
line. We quantified 4,074 unique SILAC pairs from 1,673 proteins and 89 phosphopeptides were deemed CXCL12-responsive
in biological replicates. Several well established CXCL12-responsive phosphosites such as AKT (pS473) and ERK2 (pY204)
were confirmed in our study. We also validated two novel CXCL12-responsive phosphosites, stathmin (pS16) and AKT1S1
(pT246) by Western blot. Pathway analysis and comparisons with other phosphoproteomic datasets revealed that genes
from CXCL12-responsive phosphosites are enriched for cellular pathways such as T cell activation, epidermal growth factor
and mammalian target of rapamycin (mTOR) signaling, pathways which have previously been linked to CXCL12/CXCR4
signaling. Several of the novel CXCL12-responsive phosphoproteins from our study have also been implicated with cellular
migration and HIV-1 infection, thus providing an attractive list of potential targets for the development of cancer metastasis
and HIV-1 therapeutics and for furthering our understanding of chemokine signaling regulation by reversible
phosphorylation.
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Introduction
Chemokines are small (8–12 kDa) extracellular mediators of
inflammation, chemotaxis, development and cellular survival. The
C-X-C motif ligand 12 chemokine (CXCL12), also known as
stromal cell-derived factor-1 (SDF-1) and pre-B-cell growth-
stimulating factor (PBSF), was first cloned as a soluble factor that
promoted the growth of B cell progenitors [1]. To date, two
receptors for CXCL12 have been described, CXCR4 [2,3] and
more recently, CXCR7 [4]. CXCL12 and CXCR4 knockout mice
are embryonic lethal [5,6] and signaling through the CXCL12/
CXCR4 axis has been implicated in organogenesis [7,8],
autoimmunity [9,10], WHIM syndrome (Warts, Hypogammaglob-
ulinemia, Infections, and Myelokathexis) [11], and human immu-
nodeficiency virus -1 (HIV-1) infection [12,13,14]. In addition,
increased CXCR4 expression has been observed in several types of
cancer [15] and is frequently associated with increased metastasis
and poor prognosis [16,17,18]. In the case of HIV-1, the viral
surface glycoprotein, gp120, can act as a ligand for CXCR4-
dependent signaling and influence successful infection of target cells
[14,19,20]. A CXCR4-specific small molecule inhibitor, AMD3100
(Plerixafor), was first designed as an HIV-1 entry inhibitor, but is
currently administered to mobilize hematopoietic stem cells from
the bone marrow [21] and also shows promise as an anti-cancer
therapeutic [22]. A greater understanding of CXCL12/CXCR4
signaling pathways may lead to more selective therapeutics for
diseases such as cancer and HIV-1 infection.
The receptors for CXCL12, CXCR4 and CXCR7, are seven
transmembrane receptors (7TMR) that initiate various intracellular
signal transduction pathways on a variety of cell types [23]. Unlike
CXCR7[24],CXCR4signalsthroughavarietyofheterotrimericG
proteins [23] including the pertussis toxin-sensitive Gai upon
binding either CXCL12 or HIV-1 [19,25,26]. Notable signal
transduction pathways activated by CXCL12 in transformed and
primary lymphocytes include intracellular calcium release, the
mitogen-activated protein kinases (MAPK), AKT, Rho GTPases
and NF-kB [27,28,29]. These pathways regulate basic cellular
processes such as survival, migration, proliferation, cytoskeleton
dynamics and gene expression [16,29,30].
More work is needed to understand the true breadth of
CXCL12-dependent signal transduction pathways and for poten-
tial novel regulators of these pathways. This is especially important
since our understanding of signal transduction pathways has
changed dramatically from a simple input-output scheme to a
highly interconnected network [31,32]. With this paradigm shift,
new tools and perspectives are needed to better understand
signaling networks [33,34]. Mass spectrometry-based quantitative
phosphoproteomics has emerged as an important tool to examine
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over 40,000 phosphorylation events have been detected and
catalogued, underscoring the power of this technology and
pervasiveness of cellular phosphorylation [36].
In this study, we examined CXCL12/CXCR4 signaling in an
unbiased fashion using mass spectrometry-based quantitative
phosphoproteomics. By employing stable isotope labeling with
amino acids in cell culture (SILAC) technology [37], we quantified
over 4,000 unique phosphopeptides upon CXCL12 addition to
CEM cells, a model human T cell line. A total of 89 phosphopep-
tides were deemed CXCL12-responsive, the majority of which have
not been documented in CXCL12/CXCR4 signaling. Validation
with various biochemical and bioinformatic analyses suggests that
theseCXCL12-responsivephosphositesfaithfullyreflectourcurrent
understanding of CXCL12/CXCR4. Our study has expanded the
growing list of signaling pathways involved in CXCL12 signaling
and should prove a valuable resource for future studies in areas as
diverse as autoimmunity, cancer biology, and infectious diseases.
Results
Phosphoproteome of CEM cells
To examine CXCL12 signaling via CXCR4, we took advantage
of mass spectrometry-based phosphoproteomics. We chose CEM
cells, a human lymphoblastic cell line, as a model. While CXCL12
can signal through both CXCR4 and CXCR7, only CXCR4 is
expressed in CEM cells [38]. To determine the kinetics and
concentration dependence of CXCL12 signaling, we treated CEM
cells with CXCL12 for different periods of time. Cells were lysed
and analyzed by SDS-PAGE and Western blotting using phospho-
specific antibodies to ERK1/2 (pT202/pY204) and AKT (pS473),
both of which are phosphorylated as a result of CXCL12-CXCR4
interactions [39]. The phosphorylation of AKT and ERK1/2
peaked between 5 and 10 min following CXCL12 addition,
similar to what has been observed in Jurkat cells, another
lymphoblastic T cell line [39] (Figure 1A). To gauge the
concentration of CXCL12 needed for maximal signaling activity,
we titrated CXCL12 and measured phosphorylation of AKT at
the 5 min time point. Based on this dose-response experiment, we
chose to treat CEM cells with 10 ng/mL of CXCL12 for 5 min in
all subsequent experiments (Figure 1B).
To quantify changes in the phosphoproteome of CXCL12-
stimulated CEM cells, we took advantage of SILAC technology
[37]. Cells were grown in parallel in media containing lysine and
arginine labeled with the nonradioactive heavy isotopes of
13C and
15N (‘heavy’ media) or in normal media containing natural lysine
and arginine isotopes (‘light’ media). The mass difference between
heavy and light peptides allows for sensitive measurement by the
Figure 1. Optimization and workflow of phosphoproteomic screen. (A) CEM cells were treated with 10 ng/mL of CXCL12 for varying lengths
of time and probed for AKT (pS473), total AKT, ERK1/2 (pT202/pY204), and total ERK1/2 by Western blot (see methods). (B) CEM cells were treated
with varying concentrations of CXCL12 for 5 min and probed for AKT (pS473) and GAPDH by fluorescent Western blot. Band signal intensities for
pAKT were normalized to GAPDH for each condition and divided by the GAPDH- normalized untreated sample. (C) SILAC heavy and light cell
populations were split into three separate tubes and stimulated with 10 ng/mL CXCL12 for 5 min. Denatured lysates were combined as shown,
digested with trypsin, fractionated via hydrophilic interaction chromatography (HILIC) and then immobilized metal affinity chromatography (IMAC).
Individual IMAC fractions were injected into an Orbitrap XL liquid chromatography coupled tandem mass spectrometer (LC/MS/MS) and data
analyzed with MaxQuant version 1.0.13.13 (see methods).
doi:10.1371/journal.pone.0024918.g001
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experimental samples. Aliquots of heavy and light cultures of
CEM cells were either left untreated or stimulated with 10 ng/mL
of CXCL12 for 5 min at 37uC (Figure 1C). Small aliquots were
taken from each experimental sample before processing to confirm
CXCL12 signaling activity by probing for pERK1/2 by Western
blot (data not shown). Lysates of CXCL12-treated heavy cells were
mixed with lysates from untreated light cells and conversely,
lysates of CXCL12-treated light cells were mixed with lysates of
untreated heavy cells. One heavy-stimulated sample pair (HS) was
analyzed, as were two light-stimulated sample pairs, LS1 and LS2.
In addition, LS1 was split into two aliquots that were each
analyzed independently by mass spectrometry providing a pair of
technical replicates termed LS1a and LS1b. In our study, we
define a pair of biological replicates as being HS and either LS1a,
LS1b, or LS2.
To resolve phosphopeptides, which are significantly lower in
abundance than unphosphorylated peptides, we followed the
protocol developed by McNulty and Annan [40]. Tryptic peptide
mixtures were first fractionated with hydrophilic interaction
chromatography (HILIC) followed by immobilized metal affinity
chromatography (IMAC) to enrich for phosphopeptides
(Figure 1C). From the four independent LC/MS/MS runs, we
identified a total of 5,013 unique phosphopeptides from 1,780
different proteins (Table S1). 65% of these phosphosites have been
cataloged in the ELM phosphosite repository [36] and in a recent
phosphoproteomic study of Jurkat cells [41]. The relative
stoichiometry of phosphorylated serine, threonine and tyrosine
(pS:pT:pY) sites detected, 79:20:1, reflects our enrichment strategy
and is consistent with similar studies [42,43,44] (Figure 2A). Only
when a heavy and light peptide pair (a SILAC pair) within a given
sample is detected by the mass spectrometer can the relative
abundance of a phosphopeptide be determined. About 1,200
SILAC pairs were detected in each experiment, with an average
40.863.5% (mean 6 standard deviation) shared between any pair
of experimental samples. There was no statistical difference
between the average overlaps of technical replicate and biological
replicate comparisons (38.4 vs. 43.0, respectively; p=0.2, Mann
Whitney). From all four replicates, 4,074 unique SILAC pairs were
identified from 1,673 proteins.
CXCL12-regulated phosphoproteome
We established two criteria to identify phosphopeptides that
were potentially regulated by CXCL12. First, the change in
phosphopeptide abundance upon CXCL12 addition must be
increased or decreased by $1.5-fold. Second, a phosphopeptide
must be consistently regulated in two or more biological replicates
- the HS sample and any two of the LS1a, LS1b or LS2 samples.
While both heavy and light stimulations have not been routinely
included in published quantitative phosphoproteomics studies, this
criterion reduces potential false positives resulting merely from
CXCL12-independent differences in peptide abundances between
the heavy and light cells. We reasoned that phosphosites that are
strongly regulated by CXCL12 would be detected in biological
replicates regardless of potential variations due to heavy and light
media preparations or due to biological variability.
Compared to unphosphorylated peptides, 11.062.5 (mean 6
STD) times more phosphopeptides increased in abundance $1.5-
fold upon CXCL12 treatment, indicating a good degree of
specificity (Figure 2B). This is consistent with the fact that cells
were treated with CXCL12 for only 5 min - enough time for
changes in phosphorylation via CXCR4-dependent signaling, but
not enough time for many proteins to change in overall abundance
due to either degradation or enhanced protein synthesis. Ratios of
protein abundance can also be derived through quantification of
several unphosphorylated peptides from the same protein. Using
this approach, we found that only one out of 3,187 proteins
consistently changed in abundance more than 1.5-fold in
biological replicates. In contrast, 89 phosphopeptides from 81
proteins consistently changed in abundance by at least 1.5-fold
between any pair of biological replicates. Mass spectrometry
details of these phosphopeptides are included in Table S2. In
addition, some phosphopeptides exhibited variable changes in
abundance between biological replicates, increasing by $1.5-fold
in at least one sample while decreasing by $1.5-fold in another, as
has been reported by others [45]. Such differences may be due to
CXCL12-independent differences in phosphopeptide abundance
between the heavy and light cell populations, perhaps linked to the
fact that these cells were propagated independently for about two
weeks. To test this possibility, we treated independent cultures of
CEM cells with CXCL12 as before and probed by Western blot
with antibodies specific for PLK (pT210) and PBK (pT9), both of
which appeared up-regulated in at least one light-stimulated
sample, yet were down-regulated in the heavy-stimulated sample.
As shown in Figure 3C, these phosphosites were unresponsive to
Figure 2. Characteristics of phosphoproteomic results. (A) When
comparing the frequencies of phosphorylated serine (pS), threonine
(pT) and tyrosine (pY) detected in all samples combined, pS is the
predominant phosphorylated amino acid in our study. (B) Frequency
distribution of SILAC ratios from phosphorylated peptides (n=2,003)
are compared to unphosphorylated peptides (n=9,316). The LS1a
sample is shown.
doi:10.1371/journal.pone.0024918.g002
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and light cell populations.
Validation of CXCL12-responsive phosphosites
To validate the CXCL12-responsive phosphosites, we com-
pared them to known CXCL12-responsive phosphosites and also
tested novel ones with phosphospecific antibodies by Western blot.
About 50 phosphosites have been shown to be regulated by
CXCL12 at different times in diverse cell types. Since we
examined only a single time point in a single cell type, only a
subset of these phosphosites would likely be detected in our study.
Indeed, eight of these phosphopeptides were detected as SILAC
pairs in biological replicates. AKT1 (pS473), ERK2 (pY204),
GSK3B (pS9) and RSK1 (pS363), all known CXCL12-responsive
phosphosites [28,46,47], surpassed the 1.5-fold change in
biological replicates (Table 1). In addition, the autophosphory-
lation site of PAK2 (pS141) and the homologous site in PAK4
(pS181), which correlate with its kinase activity, also increased
upon CXCL12 addition [48]. Two other phosphosites previously
shown to be regulated by CXCL12, RPS6 (pS235, pS236),
increased 1.5- fold, but in only one biological replicate and so did
not meet our criteria [49].
Figure 3. Validation of phosphosites detected by mass spectrometer. CEM cells were treated with 10 ng/mL of CXCL12 for 5 min and lysates
analyzed by Western blot using antibodies for (A) stathmin (pS16), total stathmin, AKT1S1 (pT246), total AKT1S1, (B) CDK1 (pY15), tubulin, Rb (pS795),
total Rb (C) PLK1 (pT210), PBK (pT9), and tubulin by Western blot. Nocodazole arrested cells were generated by treating CEM cells with 50 ng/mL
nocodazole for 16 hours. Fluorescent Western blot fold-changes were calculated by normalizing their integrated intensities to tubulin for each
condition, then dividing by the tublin-normalized untreated sample.
doi:10.1371/journal.pone.0024918.g003
Table 1. SILAC ratios of previously published CXCL12-responsive phosphosites.
SILAC ratio (log2) per sample
Gene symbol (alias) Gene name Phosphosite
a Sequence window LS1a LS1b LS2 HS
AKT1 v-akt murine thymona viral oncogene homolog 1 473 PHFPQFpSYSASGT ND 1.86 ND 0.95
MAPK1 (ERK2) mitogen-activated protein kinase 1 187 TGFLTEpYVATRWY 1.79 2.15 1.75 0.63
GSK3B glycogen synthase kinase 3 beta 9 GRPRTTpSFAESCK 0.68 0.61 0.56 0.63
RPS6KA1 (RSK1) ribosomal protein S6 kinase, 90 kDa, polypeptide 1 372 SRTPKDpSPGIPPS 0.19 0.62 0.57 0.97
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 141 VKQKYLpSFTPPEK 0.64 0.57 1.62 1.03
PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 181 RDKRPLpSGPDVGT 0.58 ND 1.01 1.27
RPS6 (S6) ribosomal protein S6 235 AKRRRLpSSLRAST 1.45 ND 2.21 20.39
RPS6 (S6) ribosomal protein S6 236 KRRRLSpSLRASTS 1.38 0.22 2.16 20.39
aPhosphosite coordinate is based off of International Protein Index database version 3.52, N.D.=not detected.
doi:10.1371/journal.pone.0024918.t001
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probing with phospho-specific antibodies by Western blot
(Figure 3). Details of these phosphosites are listed in Table 2.
From independent experiments, Stathmin (pS16) and AKT1S1
(pT246), also referred to as PRAS40, both increased in abundance
in CEM cells following CXCL12 addition, though neither has
been previously linked to CXCL12 signaling (Figure 3A). Stathmin
is a small microtubule binding protein that regulates the rates of
polymerization and disassembly, or catastrophe, of microtubule
chains and both phosphosites that were CXCL12-responsive, S16
and S25, have documented roles in regulating its activity [50].
AKT1S1, or PRAS40, is an Akt substrate that regulates mTOR
signaling [51]. We also tested two phosphosites that were not
considered CXCL12-responsive sites by our criteria, but had
SILAC ratios reported in biological replicates. As expected,
phosphosites from Rb (pS795) and CDK1 (pY15) showed no
response to CXCL12 as determined by Western blot, making
these true negatives (Figure 3C). In total, the SILAC ratios of 10/
12 phosphosites were confirmed as being either up-regulated or
unchanged by CXCL12 addition by independent Western blots
and literature mining, consistent with the SILAC ratios deter-
mined from our experiments.
Cellular pathways involved in CXCL12 signaling
Since phosphospecific antibodies do not exist for the majority of
the CXCL12-responsive phosphosites, we sought to validate our
dataset at the level of cellular pathways. We compared the
corresponding genes of each CXCL12-responsive phosphosite to
the Kyoto Encyclopedia of Genes and Genomes (KEGG) curated
pathway database [52]. Table 3 lists the ten most significantly
enriched pathways. While T cell receptor signaling (hsa04660) and
ErbB (hsa04012) were the only pathways from the KEGG
database that achieved a statistically significant degree of
enrichment, the majority of the enriched pathways identified in
our screen have also been previously implicated in CXCL12
signaling, including both the mammalian target of rapamycin
(mTOR) and MAPK signaling pathways [27,53]. In addition,
CXCL12 can provide costimulatory signals during T cell
activation [47,54] and transactivate HER-2 (ErbB-2) signaling in
various cancer cells [55,56]. To further test these associations, we
calculated the enrichment, or overlap, of genes from two recent
phosphoproteomic studies examining T cell receptor (TCR) and
epidermal growth factor (EGF) signaling within genes from
CXCL12-responsive phosphosites [41,42]. Mayya et al. examined
the phosphoproteome following TCR signaling that was induced
by CD3 cross-linking after 5, 15 or 60 min [41]. We found a
significant enrichment of genes from CD3-responisve phosphosites
(15 min time point) within genes from CXCL12-responsive
phosphosites (p=3.2610
25). Interestingly, overlap with the earlier
(5 min) and later (60 min) time points were much less significant,
suggesting kinetic specificity (Figure 4A). A similar kinetic
association was seen with the EGF study reported by Olsen et
al., who examined the phosphoproteome 1, 5, 10 and 20 min
following the addition of EGF to HeLa cells [42]. There was a
significant enrichment of hits from the 5 min EGF time point
(p=0.013), yet the 1, 10 and 20 min EGF time points were not
significant. While the enrichment of the mTOR signaling KEGG
pathway (hsa04150) was not statistically significant, the enrich-
ment of genes from a manually curated mTOR signaling network
[57] was highly significant in our dataset (p=5.5610
25).
CXCL12 and G protein signaling
CXCL12 activates G protein-dependent and beta-arrestin-
dependent signaling via CXCR4 [23]. To determine if the
CXCL12-responsive phosphosites we identified are consistent with
an involvement in G protein-dependent signaling, we measured
the overlap of our dataset with a recently published dataset of G
protein-dependent and independent phosphosites [44]. Christen-
sen et al. stimulated 293T cells with angiotensin II (Ang II) or
[Sar
1, Ile
4, Ile
8] angiotensin II (SII-Ang II), both of which bind to
and signal through the angiotensin II type 1 receptor (AT1R) [44].
Table 3. Enriched cellular pathways in CXCL12-responsive
phosphosites.
Term p-value
a
hsa04660:T cell receptor signaling pathway 3.22610
24
hsa04012:ErbB signaling pathway 0.0078
hsa04150:mTOR signaling pathway 0.11
hsa04010:MAPK signaling pathway 0.12
hsa05211:Renal cell carcinoma 0.14
hsa04662:B cell receptor signaling pathway 0.14
hsa04666:Fc gamma R-mediated phagocytosis 0.22
hsa04722:Neurotrophin signaling pathway 0.29
hsa04510:Focal adhesion 0.31
hsa05213:Endometrial cancer 0.31
aBenjamini and Hochberg corrected.
Enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [52] in
genes from CXCL12-responsive phosphosites were calculated in DAVID [93,94].
doi:10.1371/journal.pone.0024918.t003
Table 2. SILAC ratios of phosphosites validated by Western blot.
SILAC ratio (log2) per sample
Gene symbol (alias) Gene name Phosphosite
a Sequence window LS1a LS1b LS2 HS
STMN1 Stathmin 1 16 ELEKRApSGQAFEL 1.14 1.08 1.81 2.19
AKT1S1 (PRAS40 AKT1 substrate 1 (proline-rich) 266 PRPRLNpTSDFQKL 0.62 0.55 1.22 0.61
RB1 Retinoblastoma 1 795 PYKFPSpSPLRIPG 20.56 0.00 20.01 0.00
CDK1 Cyclin-dependent kinase 1 15 KIGEGpTpYGVVYKG 20.01 20.03 0.06 20.09
PLK1 Polo-like kinase 1 210 DGERKKpTLCGTPN ND 3.21 ND 22.68
PBK (TOPK) PDZ binding kinase 9 GISNFKpTPSKLSE 1.80 1.96 2.20 22.48
aPhosphosite coordinate is based off of International Protein Index database version 3.52, N.D.=not detected.
doi:10.1371/journal.pone.0024918.t002
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G proteins, while binding of SII-Ang II does not. We parsed the
data from Chrisensen et al. to more closely reflect the kinetics of
our experimental design and the definition of our hit threshold (see
methods) and measured the overlap of these phosphosites with the
CXCL12-responsive phosphosites and corresponding genes. The
overlap of Ang II-responsive phosphosites and genes was highly
significant (p=1.5610
25, p=2.0610
26 respectively) compared to
SII-Ang II-responsive phosphosites (p=0.054, 0.06 respectively)
(Figure 4B). Since the overlap of CXCL12-responsive phosphosites
and corresponding genes with the G protein-dependent phospho-
sites identified by Chrisensen was highly significant, we conclude
that our dataset faithfully reflects G protein-dependent CXCL12-
mediated signal transduction pathways.
Discussion
In the present study, we successfully measured the fold-change
in abundance of 4,074 phosphopeptides CEM cells, 89 of which
consistently changed in abundance upon CXCL12 addition in
biological replicates. Several independent lines of evidence suggest
that these CXCL12-responsive phosphosites faithfully reflect
CXCL12 signaling events. First, Western blot analysis of several
phosphoproteins confirmed their respective SILAC ratios. Stath-
min (pS16) and AKT1S1 (pT246), both novel CXCL12-
responsive phosphosites, increased in abundance upon CXCL12
treatment (Figure 3A). In contrast, Rb (pS795) and CDK1 (pY15)
did not change when analyzed by Western blot, confirming the
SILAC ratios (Figure 3B, Table 2). Second, cellular pathways that
are known to be involved in CXCL12 signaling were significantly
enriched in our dataset. These include T cell activation, EGF
signaling and mTOR (Table 3). We were further able to confirm
these associations by measuring the overlap of genes from other
published independent phosphoproteomic datasets examining
these pathways (Figure 4A). Lastly, a comparison of our dataset
with phosphosites from a recently published phosphoproteomic
study examining G protein biased ligands confirms that CXCL12-
responsive phosphosites reflect G protein-dependent signaling
[23,44], (Figure 4B). Biochemical and bioinformatic analyses
complemented with literature mining all reinforce the association
of our dataset with known CXCL12-dependent signaling path-
ways.
The results from this study expand not only the ever-growing list
of catalogued phosphosites - over 1,700 of the phosphopeptides we
detected are novel – but also provide a unique resource for the
advancing the study of biological processes that are regulated by
CXCR4. Only 34 of the 81 genes from our dataset are annotated
in the KEGG pathway database, thus providing an opportunity to
expand our understanding of these cellular pathway with the
knowledge that a given gene product is differentially phospho-
phorylated by CXCL12. In addition, potential functions for a
majority of CXCL12-regulated phosphosites have not yet been
defined. Figure 5 shows all genes from CXCL12-responsive
phosphosites according to published putative functions.
Our results also highlight an important consideration when
designing SILAC experiments. PLK (pT210) and PBK (pT9)
decreased $1.5-fold in the heavy-treated cells yet increased $1.5-
fold in at least one of the light treated samples (Table 2). The most
likely explanation for these inverted ratios is that these phospho-
sites are not CXCL12-responsive and had unequal abundances in
the heavy and light cell mixtures (Figure 3C). To control for
inherent differences in phosphosite abundance between heavy and
light cultures that would otherwise contribute to false positives, one
can either include a mixture of untreated heavy and light
populations or stimulate each and combine with the untreated
pair (Figure 1C). The latter strategy is often referred to as a ‘swap’
or ‘reverse labeling’ and phosphopeptides are only considered if
Figure 4. Comparison of CXCL12-responsive phosphopeptides
and corresponding genes to published phosphoproteomic and
manually curated datasets. Genes from various phosphoproteomic
datasets and manually curated databases were compared to genes
from CXCL12-responsive phosphosites using contingency tables (see
methods). Fold-enrichments are listed at the base of each bar.
Benjamini and Hochberg corrected p-values (Fisher’s exact test) are
plotted with p,0.05 considered statistically significant (solid line). (A)
Genes from CD3-responsive phosphosites (TCR) [41], epidermal growth
factor (EGF)-responsive phosphosites [42], and mitotic phosphosites
[68] were compiled as published for the indicated time points. TCR
(15 min) and EGF (5 min) are the most statistically significant,
suggesting crosstalk between pathways. Unlike cancer-related genes
[69], only HIV ‘interactors’ (http://www.ncbi.nlm.nih.gov/RefSeq/
HIVInteractions) and mammalian target of rapamycin (mTOR) signaling
genes [57] were statistically significant. (B) Phosphopeptides and
corresponding genes of G protein-dependent (Ang II) and independent
(SII-Ang II) signaling (3 min) were reanalyzed to reflect our experimental
conditions and analysis criteria (see methods) [44]. Only the overlap of
Ang II-responsive phosphosites and corresponding genes were
statistically significant.
doi:10.1371/journal.pone.0024918.g004
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added benefit to this approach is that a genuine biological replicate
is obtained concurrently [58]. A drawback is that inverted heavy
and light ratios can be due to either inherently different
phosphopeptide abundances or biological noise. When comparing
pairs of light-treated samples, LS1a, LS1b, and LS2, very few
(0.08–0.4%) of each pair’s SILAC ratios ($1.5-fold) were inverted,
suggesting that biological noise was not a major factor.
One of the phosphosites we validated in our screen, stathmin
(pS16), has not been previously shown to be regulated by
CXCL12. Stathmin is a small microtubule binding protein that
regulates microtubules dynamics [50]. While few studies have
examined the regulation of microtubules by chemokines, it is
known that CXCL12 leads to the microtubule-dependent
polarization of CEM cells [59]. Indeed, several other genes from
CXCL12-responsive phosphosites identified in our study are
known to regulate the microtubule cytoskeleton, including CLIP-
170 (pS348), EB1 (pS165), CEP170 (pS496) and EML3 (pS176),
none of which have previously been shown to be influenced by
CXCL12 signaling [60,61,62,63]. CLIP-170 (pS348) is found in a
region of the protein with a relative high density of phosphosites,
many of which can regulate its association with microtubules [64].
While the role of the human EB1 (pS165) phosphosite has not
been elucidated, a small cluster of phosphosites in the analogous
linker region of the yeast homolog, Bim1p, was recently shown to
regulate the association of Bim1p with microtubules [65]. Taken
together, our data indicate that CXCL12 signaling via CXCR4
leads to rapid phosphorylation of a number of proteins involved in
microtubule dynamics, suggesting a direct role in regulating the
cellular cytoskeleton for subsequent chemotaxis or some other
functional response.
CXCL12/CXCR4 signaling has become increasingly implicat-
ed with various human cancers. In various types of tumors,
CXCL12 can promote migration, cellular survival, and at times,
proliferation [17,66]. Genes from CXCL12-responsive phospho-
sites that have been linked to cellular migration are indicated in
Figure 5. Consistent with previous reports [47,67], we also did not
observe increases in CDK1 (pY15) or H3 (pS10) phosphorylation,
both hallmarks of cell cycle progression, upon CXCL12 addition
to CEM cells at the time point studied (Figure 3B, data not shown).
Figure 5. Compilation of genes from CXCL12-responsive phosphosites. Putative cellular localizations and functions of each gene are
indicated as described in the literature. While some genes belong to multiple functional categories, only common associations are listed. Genes are
marked with a colored circle where published experimental evidence exists to link a particular gene to HIV infection (blue), cellular migration (yellow)
or both.
doi:10.1371/journal.pone.0024918.g005
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enriched in our dataset (p=0.073) nor were genes from a
manually curated collection of cancer related genes [68,69]
(p=0.20) (Figure 4A). The mTOR pathway has been linked to
cancer cell migration and our data support a model of signal
cross-talk between CXCR4 and mTOR during cancer cell
metastasis [53,70] (Figure 4A). For example, recent work has
shown that RICTOR, a member of the mTOR pathway, is
required for neutrophil chemotaxis yet a connection between
RICTOR and CXCR4 signaling has not been documented [71].
From our dataset, RICTOR contains two CXCL12-responsive
phosphosites, pS1282 and pS1302. While the function of these
phosphosites during CXCL12 chemotaxis has not been docu-
mented, these phosphosites may regulate RICTOR-dependent
chemotaxis.
C X C R 4i sa l s oac o r e c e p t o rf o rh u m a ni m m u n o d e f i c i e n c y
v i r u s - 1( H I V - 1 )a n da ni m p o r t a n tf o c u so fr e s e a r c hi nH I V - 1
biology [13,14,72]. In support of this, genes from a curated
functional HIV interaction database from NCBI were signifi-
cantly enriched in CXCL12 hits (p=4.4610
24)( F i g u r e4 A ) .I n
total, 23 of the 78 genes in our dataset have a documented role
in HIV infection (Figure 5), several of which have diverse roles in
HIV infection. For example, BMP2K has been shown to be
important for early steps in HIV infection [73], HMGA1 and
XRCC6 have been implicated in HIV integration into host
genomic DNA [74,75] and GATA3, SFRS7, SNW1 have all
been linked to HIV gene expression [76,77,78]. Little is known
of the roles of phosphorylation or CXCR4 signaling on the
activity of these proteins, yet HIV may modulate the activity of
these proteins in a CXCR4-dependent manner to facilitate
infection of the target cell. This is certainly plausible since it has
already been demonstrated that cellular signals transduced by
HIV during entry can affect multiple stages of the HIV lifecycle
[79,80,81]. A growing body of work has also implicated CXCR4
and various chemokines in regulating infection of resting CD4
+
T cells [80,82,83,84], an important latent reservoir of HIV in
infected individuals [85]. Therefore, it’s plausible that CXCL12-
responsive phosphoproteins from our study may regulate entry
and integration of resting CD4
+ T cells. Future studies can also
address potential differences between signaling of CXCR4 and
CCR5, another HIV-1 coreceptor, since differential engagement
of these chemokine receptors can have unique effects on target
gene expression [86] and host factor requirements for infection
of primary cells [87]. In all, our study uncovered several
members of signal transduction pathways that HIV-1 may
modulate in order to successfully infect T cells, of which
targeting has become an attractive avenue for anti-HIV-1
therapeutics [88].
O’Hayre et al. recently published a study examining the
phosphoproteome of CXCL12-treated primary chronic lympho-
cytic leukemia cells, a cancer of B cells [89]. Our studies differ in
target cell (B vs. T cells), phosphopeptide enrichment strategy
(IMAC alone vs. HILIC and IMAC), and method of quantifica-
tion (semi-quantitative label-free spectral counting vs. SILAC). Of
the 13 phosphoproteins reported by O’Hayre et al. to have
spectral counts suggestive of CXCL12-responsiveness, only half
were detected as SILAC pairs by at least one phosphopeptide in
our analysis, yet none were considered CXCL12-responsive.
Interestingly, both of our studies detected novel CXCL12-
responsive AKT substrates, PDCD4 (pS457) [89] and AKT1S1
(pT246) (Figure 3A), underscoring the potential role of AKT
signaling and leukemias [90].
Phosphoproteomic examination of signaling pathways is poised
to greatly advance signal transduction research in areas such as
basic science [42], clinical therapeutics [91] and perhaps even
drug design [33]. Our study greatly expands the breadth and
diversity of early changes in the CXCL12/CXCR4 signaling
network. We have shown through multiple independent means of
validation that our dataset is consistent with what is currently
understood about CXCL12/CXCR4 signaling. We confirmed
associations with various signaling pathways that have already
been described, e.g. T cell activation, EGF, and mTOR, and
highlighted perhaps under-appreciated associations such as with
microtubule dynamics. Our study also uncovered several phos-
phoproteins that may regulate cancer metastasis and HIV-1
infection of T cells, providing new avenues to expanding not only
our basic understandings of these diseases but also to identify novel
therapeutics.
Materials and Methods
CXCL12 treatment of CEM cells
CCRF-CEM cells (ATCC CCL-119) were cultured in RPMI-
1640 with 10% (v/v) FBS, 100 units/mL of penicillin and 100 mg/
mL streptomycin. For SILAC labeling, cells were cultured in
RPMI lacking lysine or arginine (AthenaES) supplemented with
200 mg/L
13C6,
15N4 arginine, 40 mg/L
13C6,
15N2 lysine
(Cambridge Isotopes) and 10% dialyzed FBS (Invitrogen 26400-
036) for eight doublings. For proteomic experiments, cells were
serum-starved overnight at a density of 1610
6 cells/mL in SILAC
media. CXCL12 (Invitrogen PHC1346) stimulations (10 ng/mL
final) were done in fresh serum-free SILAC media at 5610
6 cells/
mL for 5 min. Cell suspensions were mixed with ice-cold PBS
containing 16phosphatase inhibitors (Sigma P5726, P0044) and
centrifuged at 1500 RPM for 5 min at 4uC. Pellets were frozen on
dry ice.
Protein hydrolysis
Cell pellets were removed from storage at 280uC and placed
on ice. Lysis buffer (0.3% SDS, 30 mM Tris, 20 mM HCl,
pH 7.8, 3.8 mM MgCl2) with protease inhibitors (Sigma P2714)
was used to disrupt the cell pellet (,1 mL/50 uL cell pellet) and
heated at 90uC for 5 min. The sample was incubated with 5
Units of benzonase (Novagen 70664-3) for 10 min at room
temperature. Cysteines were alkylated by the addition of 50 mM
iodoacetamide and kept in the dark for 30 min. Proteins were
precipitated with 5 volumes of acetone and kept at 220uCf o r
2 hours to overnight. Protein precipitant was centrifuged
(14,0006 g, 15 min) and the pellet washed 26 with 80%
acetone. The proteins were digested with 40 ug trypsin (Promega
V511A) in 500 uL of 40 mM NH4HCO3,0 . 1 %R a p i g e s ta c i d
labile surfactant (Waters 186001861) at 37uC overnight. Before
trypsin addition, protein content was measured using the
Bradford assay. Rapigest was hydrolyzed with formic acid
(2.5% v/v final concentration) for 1 hour at room temperature
and centrifuged at 14,0006g for 20 min. Tryptic peptides were
cleaned with a C18 Sep-Pak (Waters WAT036820) eluting with
2 mL 75%, 0.1% formic acid. Peptide concentrations were
estimated by UV spectrophotometry @ 280 nm and equal
amounts from isotopically heavy and light samples were mixed
together.
Hydrophilic interaction chromatography
The protocol of McNulty and Annan for phosphoproteome
characterization utilizes hydrophilic interaction chromatography
(HILIC) as a first dimension separation of tryptic peptides, the idea
being that the more hydrophilic phosphopeptides are separated
from the non-phosphopeptides thus facilitating capture by
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selectivity [40]. HILIC was performed on a Beckman-Coulter
System Gold HPLC with the following conditions: column,
TSKgel Amide 80 4.6 mm6250 mm (Tosoh Biosciences);
Buffers, A- 0.1% TFA in water, B- 90% CH3CN 0.1% TFA;
Flow, 0.5 mL/minute; Equilibrate column 85% B 15% A, 1 to
2 mg. peptide in 0.5 mL 90% CH3CN 0.1% HCOOH loaded at
85% B for 10 min; Gradient, 85% to 70% B over 40 min, 70% to
10% B over 5 min, hold 10% B 5 min, return to 85% B over
2 min; Collect 2 min fractions from t=5 to 65 min in 1 mL
deepwell plate (Eppendorf C5096-0112). Ten percent of each
fraction was reserved for whole proteome analysis and the
remaining 90% of each fraction was used for phosphopeptide
enrichment.
Phosphopeptide Enrichment
Phosphopepitdes were enriched from the HILIC fractions using
immobilized metal affinity chromatography in batch mode. Phos-
Select Iron Affinity Beads (Sigma P9740) were added directly to
the HILIC fractions (50 uL of 20% evenly suspended slurry) and
mixed end over end for 30 min at room temperature. Fractions
were transferred to 0.22 um centrifuge filter devices and
centrifuged to remove the filtrate. Beads were washed with
300 uL 30% CH3CN, 250 mM AcOH, followed by a wash with
water. Filtrates were discarded and phosphopeotdes eluted from
the beads with 150 uL 400 mM NH4OH. After 10 min
incubation, filtrates were recovered and lyophilized. Samples were
reconstituted with 13 uL 0.1% HCOOH for analysis by mass
spectrometry.
Mass Spectrometry Analysis
Tryptic digests were analyzed on a hybrid LTQ Orbitrap mass
spectrometer (Thermofisher Scientific, San Jose, CA) coupled with
a NanoLC pump (Eksigent Technologies) and autosampler.
Tryptic peptides were separated by reverse phase (RP)-HPLC on
a nanocapillary column, 75 mmi d 620 cm ProteoPep (New
Objective, Woburn, MA, USA). Mobile phase A consisted of
1% methanol/0.1% formic acid and mobile phase B of 1%
methanol/0.1% formic acid/79% acetonitrile. Peptides were
eluted into the mass spectrometer at 300 nL/min with each RP-
LC run comprising a 15 min sample load at 3% B and a 90 min
linear gradient from 5 to 45% B. The mass spectrometer was set to
repetitively scan m/z from 300 to 1800 (R=100,000 for LTQ-
Orbitrap) followed by data-dependent MS/MS scans on the six or
ten most abundant ions, with a minimum signal of 1000, isolation
width of 2.0, normalized collision energy of 28, and waveform
injection and dynamic exclusion enabled. FTMS full scan AGC
target value was 1e6, while MSn AGC was 5e3, respectively.
FTMS full scan maximum fill time was 500 ms, while ion trap
MSn fill time was 50 ms; microscans were set at one. FT preview
mode, charge state screening, and monoisotopic precursor
selection were all enabled with rejection of unassigned and 1+
charge states.
Sequence database searching
Raw MS files were processed using MaxQuant (version
1.0.13.13) [92]. The .msm output files were searched against the
International Protein Index human protein sequence database
(version 3.52, concatenated with reversed decoy sequences and
contaminants) using MASCOT search algorithm (Matrix Science,
version 2.3). Fragment ion tolerance was set to 0.6 Da, with a
maximum of one missed tryptic cleavage site. S-Carbamidomethyl
cysteine was defined as a fixed modification while oxidized
methionine, phospho-serine, phospho-threonine and phospho-
tyrosine were selected as variable modifications. The false-
discovery rate for peptides and proteins was set at 0.01. Reported
phosphopeptide ratios were not used for calculating the protein
ratios.
Western blots
Cell pellets were dissolved in 1% triton x-100, 150 mM NaCl,
5 mM EDTA, phosphatase inhibitors (Sigma P5726, P0044)
and a protease inhibitor cocktail (Roche 1836170) for 5 min on
ice, then clarified by centrifugation at 20,0006 g for 10 min.
Lysates were denatured with LDS sample buffer (Invitrogen
NP0007) with 2.5% (v/v) beta-mercaptoethanol and incubated
at 70uC for 10 min. Samples were run on 10% Bis-Tris gels
(Invitrogen NP0303) for 40 min at 200 V. Gels were transferred
to PVDF membranes and blocked for 30 min in 5% (w/v)
evaporated milk. Blots incubated at 4uCo v e r n i g h tw i t ha
1:1,000 dilution of primary antibodies. Antibodies against AKT
(pS473), ERK1/2 (pT202/pY204), Stathmin (pS16), Stathmin,
AKT1S1, a-tubulin, PBK (pT9), PLK1 (pT210) CDK1 (pY15),
H3 (pS10), Rb (pS795), and Rb were obtained from Cell
Signaling Technology. AKT1S1 (pT246) was obtained from
Invitrogen and GAPDH from Calbiochem. HRP secondary
antibodies (Jackson Labs) were used at 1:20,000 for 30 min and
antibodies for fluorescent blots, anti-rabbit 680 (Alexa, Invitro-
gen) and anti-mouse 800 (Rockland), were used at 200 ng/mL
for 30 min.
Pathway analysis and comparisons of datasets
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis was done with DAVID [93,94] (http://
david.abcc.ncifcrf.gov) with default settings. Genes from all
detected phosphopeptides served as a background. The fold-
enrichment i.e., overlap, of a given dataset (dataset X) within
CXCL12-responsive phosphosites or genes was determined with
contingency tables by dividing the frequency of phosphosites or
genes from dataset6within CXCL12-responsive phosphosites or
genes by the frequency of phosphosites or genes from data-
set6within CXCL12-nonresponsive phosphosites or genes. For
comparisons with angiotensin phosphoproteomic data [44],
were reanalyzed such that phosphopeptides at a given time post-
stimulation were considered ‘hits’ if regulated 1.5-fold in both
biological replicates. Cancer related genes [69] were obtained
f r o mt h eW e l l c o m eT r u s tS a n g e rI n s t i t u t eC a n c e rG e n o m e
Project web site, http://www.sanger.ac.uk/genetics/CGP. HIV
interactor genes were obtained from (http://www.ncbi.nlm.nih.
gov/RefSeq/HIVInteractions).
Statistical Analysis
Significance for KEGG cellular pathway enrichments were
determined in DAVID [93,94]. P-values for fold-enrichments
between datasets were calculated with the one-sided Fisher’s exact
test (R version 2.12.0). All p-values were adjusted for multiple
comparisons using the Benjamini and Hochberg method in R.
Supporting Information
Table S1 Detailed information from MaxQuant searches of
CEM phosphoproteome.
(XLS)
Table S2 Detailed information from MaxQuant searches of
CXCL12-responsive phosphopeptides.
(XLS)
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